Intravenous Tramadol and Magnesium Sulphate for Prevention of Shivering

Launched by AL-AZHAR UNIVERSITY · Sep 23, 2024

Keywords

ClinConnect Summary

This clinical trial is looking at two different medications, intravenous (IV) tramadol and magnesium sulphate, to see which one is more effective in preventing shivering during spinal anesthesia for patients undergoing certain surgeries. Shivering can be a common reaction after anesthesia, and the goal of this study is to find the best way to manage it.

To participate in this trial, individuals should be between the ages of 76 and 91 and have an ASA physical status of I or II, meaning they are generally healthy or have mild medical issues. However, people with serious health problems, allergies to the medications being tested, or certain conditions that make spinal anesthesia unsafe will not be eligible. If you decide to participate, you will receive one of the two medications before your surgery, and the research team will monitor you for any side effects and the effectiveness of the treatment.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • - American Society of Anesthesiologists (ASA) I and II physical status undergoing an elective surgery under spinal anesthesia.
• Exclusion Criteria:
• • history of uncontrolled comorbidities, cardiac, respiratory, renal or hepatic disease, patients who had allergy to any medication in the study, contraindications to spinal anesthesia (coagulation disorder, infection at site of puncture, raised intracranial tension or any spine deformity), fever \>38 Celsius or less than 36 Celsius, body mass index more than 35 and who has history of alcohol intake